Brainstorm Cell Therapeutics Inc. (BCLI)

Market Cap	11.07M +51.6%
Revenue (ttm)	n/a
Net Income	-10.52M
EPS	-0.95
Shares Out	14.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,513
Open	0.7518
Previous Close	0.7700
Day's Range	0.7518 - 0.8349
52-Week Range	0.4589 - 1.6900
Beta	0.26
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the deve...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 19
• Stock Exchange: OTCMKTS
• Ticker Symbol: BCLI

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 23, 2026

Data Sources Report a data error